Previous 10 | Next 10 |
4 Cheap Stocks To Watch This Week Penny stocks are definitely considered “affordable” but let’s not get than confused with “cheap”. When it comes to these small- and micro-cap companies, the price tag of the stock itself shouldn’t be the only thing y...
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. "For the first time in ten years, we were unable to host our mid-year conference, which ...
BEDMINSTER, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a fireside chat during the BTIG Virtual Biotech Conference 2020 on Tuesday, August ...
BEDMINSTER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live aud...
Matinas BioPharma Holdings (NYSEMKT: MTNB ) has commenced enrollment and started dosing patients in the ENHANCE-IT study and expects to resume dosing patients in the EnACT (Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial ) study imminently, following necessary r...
- Topline data from ENHANCE-IT study of MAT9001 vs. Vascepa® expected in Q1 2021 - - EnACT remains on track for cohort progression in Q4 2020 - BEDMINSTER, N.J., June 30, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings...
BEDMINSTER, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a company overview during the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2...
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Peter Vozzo - Investor Relations Jerry Jabbour - Chief Executive Officer Terry Ferguson - Chief Medical Officer Terri Matkovits - Chief Development Officer C...
– ENHANCE-IT study of MAT9001 against Vascepa ® set to resume in June 2020 – – EnACT study of MAT2203 in cryptococcal meningitis expected to resume in June 2020 – – Management to host conference call today, Monday, May 11 th , at 4:30 p.m. ...
BEDMINSTER, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audi...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
Matinas Biopharma Holdings Inc. Website:
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful...
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its ora...
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...